K

Kiniksa Pharmaceuticals Ltd
D

KNSA

78.780
USD
0.24
(0.31%)
قبل الجلسة·78.590USD-0.190(-0.24%)
حجم التداول
28,381
الربح لكل سهم
1
العائد الربحي
-
P/E
80
حجم السوق
6,146,731,744
أصول ذات صلة

العنوان: Kiniksa Pharmaceuticals International plc

القطاع: الرعاية الصحية
الصناعة: Drug Manufacturers - Specialty & Generic
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.